




# UK Standards for Microbiology Investigations

## Vertical and Perinatal Transmission of Hepatitis C



## Acknowledgments

UK Standards for Microbiology Investigations (SMIs) are developed under the auspices of Public Health England (PHE) working in partnership with the National Health Service (NHS), Public Health Wales and with the professional organisations whose logos are displayed below and listed on the website <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>. SMIs are developed, reviewed and revised by various working groups which are overseen by a steering committee (see <https://www.gov.uk/government/groups/standards-for-microbiology-investigations-steering-committee>).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the Medical Editors for editing the medical content.

For further information please contact us at:

Standards Unit  
Microbiology Services  
Public Health England  
61 Colindale Avenue  
London NW9 5EQ

E-mail: [standards@phe.gov.uk](mailto:standards@phe.gov.uk)

Website: <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>

UK Standards for Microbiology Investigations are produced in association with:



Logos correct at time of publishing.

## Contents

---

<b>ACKNOWLEDGMENTS .....</b>	<b>2</b>
<b>AMENDMENT TABLE .....</b>	<b>4</b>
<b>UK STANDARDS FOR MICROBIOLOGY INVESTIGATIONS: SCOPE AND PURPOSE.....</b>	<b>5</b>
<b>SCOPE OF DOCUMENT .....</b>	<b>8</b>
<b>VERTICAL AND PERINATAL TRANSMISSION OF HEPATITIS C .....</b>	<b>9</b>
<b>NOTIFICATION TO PHE OR EQUIVALENT IN THE DEVOLVED ADMINISTRATIONS .....</b>	<b>11</b>
<b>REFERENCES .....</b>	<b>12</b>



NICE has accredited the process used by Public Health England to produce Standards for Microbiology Investigations. Accreditation is valid for 5 years from July 2011. More information on accreditation can be viewed at [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

## Amendment Table

Each SMI method has an individual record of amendments. The current amendments are listed on this page. The amendment history is available from [standards@phe.gov.uk](mailto:standards@phe.gov.uk).

New or revised documents should be controlled within the laboratory in accordance with the local quality management system.

Amendment No/Date.	3/03.11.14
Issue no. discarded.	1.2
Insert Issue no.	2
Section(s) involved	Amendment
Whole document.	Hyperlinks updated to gov.uk.
Page 2.	Updated logos added.
Title.	Title of document and flowchart changed to 'Vertical and perinatal transmission of Hepatitis C'.
Scope.	'Scope' section added to the document. Links to UK SMI documents added and definitions of test results (for example reactive, non-reactive) included. Clarification of when testing should be carried out: 'Only babies born from mothers who are HCV RNA positive require routine testing, however babies born from mothers who are HCV RNA negative, anti HCV antibody positive may be tested dependent on local policy.'
Flowchart.	Flowchart updated in line with definitions in the scope. Report comments updated. Order of tests updated. Time frames for testing updated.
Footnotes.	Footnotes expanded to include information on perinatal transmission, when/who to test, and sensitivity of tests.
References.	Some references updated.

# UK Standards for Microbiology Investigations<sup>#</sup>: Scope and Purpose

---

## Users of SMIs

- SMIs are primarily intended as a general resource for practising professionals operating in the field of laboratory medicine and infection specialties in the UK.
- SMIs provide clinicians with information about the available test repertoire and the standard of laboratory services they should expect for the investigation of infection in their patients, as well as providing information that aids the electronic ordering of appropriate tests.
- SMIs provide commissioners of healthcare services with the appropriateness and standard of microbiology investigations they should be seeking as part of the clinical and public health care package for their population.

## Background to SMIs

SMIs comprise a collection of recommended algorithms and procedures covering all stages of the investigative process in microbiology from the pre-analytical (clinical syndrome) stage to the analytical (laboratory testing) and post analytical (result interpretation and reporting) stages.

Syndromic algorithms are supported by more detailed documents containing advice on the investigation of specific diseases and infections. Guidance notes cover the clinical background, differential diagnosis, and appropriate investigation of particular clinical conditions. Quality guidance notes describe laboratory processes which underpin quality, for example assay validation.

Standardisation of the diagnostic process through the application of SMIs helps to assure the equivalence of investigation strategies in different laboratories across the UK and is essential for public health surveillance, research and development activities.

## Equal Partnership Working

SMIs are developed in equal partnership with PHE, NHS, Royal College of Pathologists and professional societies.

The list of participating societies may be found at <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>.

Inclusion of a logo in an SMI indicates participation of the society in equal partnership and support for the objectives and process of preparing SMIs. Nominees of professional societies are members of the Steering Committee and Working Groups which develop SMIs. The views of nominees cannot be rigorously representative of the members of their nominating organisations nor the corporate views of their organisations. Nominees act as a conduit for two way reporting and dialogue. Representative views are sought through the consultation process.

SMIs are developed, reviewed and updated through a wide consultation process.

---

<sup>#</sup>Microbiology is used as a generic term to include the two GMC-recognised specialties of Medical Microbiology (which includes Bacteriology, Mycology and Parasitology) and Medical Virology.



## Quality Assurance

NICE has accredited the process used by the SMI Working Groups to produce SMIs. The accreditation is applicable to all guidance produced since October 2009. The process for the development of SMIs is certified to ISO 9001:2008.

SMIs represent a good standard of practice to which all clinical and public health microbiology laboratories in the UK are expected to work. SMIs are NICE accredited and represent neither minimum standards of practice nor the highest level of complex laboratory investigation possible. In using SMIs, laboratories should take account of local requirements and undertake additional investigations where appropriate. SMIs help laboratories to meet accreditation requirements by promoting high quality practices which are auditable. SMIs also provide a reference point for method development.

The performance of SMIs depends on competent staff and appropriate quality reagents and equipment. Laboratories should ensure that all commercial and in-house tests have been validated and shown to be fit for purpose. Laboratories should participate in external quality assessment schemes and undertake relevant internal quality control procedures.

## Patient and Public Involvement

The SMI Working Groups are committed to patient and public involvement in the development of SMIs. By involving the public, health professionals, scientists and voluntary organisations the resulting SMI will be robust and meet the needs of the user. An opportunity is given to members of the public to contribute to consultations through our open access website.

## Information Governance and Equality

PHE is a Caldicott compliant organisation. It seeks to take every possible precaution to prevent unauthorised disclosure of patient details and to ensure that patient-related records are kept under secure conditions.

The development of SMIs are subject to PHE Equality objectives <https://www.gov.uk/government/organisations/public-health-england/about/equality-and-diversity>. The SMI Working Groups are committed to achieving the equality objectives by effective consultation with members of the public, partners, stakeholders and specialist interest groups.

## Legal Statement

Whilst every care has been taken in the preparation of SMIs, PHE and any supporting organisation, shall, to the greatest extent possible under any applicable law, exclude liability for all losses, costs, claims, damages or expenses arising out of or connected with the use of an SMI or any information contained therein. If alterations are made to an SMI, it must be made clear where and by whom such changes have been made.

The evidence base and microbial taxonomy for the SMI is as complete as possible at the time of issue. Any omissions and new material will be considered at the next review. These standards can only be superseded by revisions of the standard, legislative action, or by NICE accredited guidance.

SMIs are Crown copyright which should be acknowledged where appropriate.

### **Suggested Citation for this Document**

Public Health England. (2014). Vertical and Perinatal Transmission of Hepatitis C. UK Standards for Microbiology Investigations. V 8 Issue 2. <https://www.gov.uk/uk-standards-for-microbiology-investigations-smi-quality-and-consistency-in-clinical-laboratories>

## Scope of Document

---

### Type of specimen

Blood

### Scope

This virology algorithm outlines the laboratory screening for HCV infection in babies born to hepatitis C virus (HCV) infected mothers<sup>1</sup>. Infection may be acquired through vertical or perinatal transmission<sup>2,3</sup>. Only babies born from mothers who are HCV RNA positive require routine testing, however babies born from mothers who are HCV RNA negative, anti-HCV antibody positive may be tested dependent on local policy. Transmission from HCV RNA negative mothers is rare, but has been documented in some studies<sup>4-6</sup>.

CE marked assays should be evaluated and verified prior to use. If assays are to be used outside of the scope of their CE marking they should be validated, and shown to be fit for purpose.

Refer to [S 1 - Acute Infective Hepatitis](#) and [G 5 – Investigation of Hepatitis](#) for further information regarding clinical presentations of acute infective hepatitis, treatment and associated tests.

This SMI should be used in conjunction with other SMIs.

### Definitions

For all antigen, antibody and NAAT testing the following definitions apply:

Reactive – Initial internal-stage positive result pending confirmation.


Not reactive – Initial internal-stage negative result.

Detected – Report-stage confirmed reactive result.

Not detected – Report-stage not reactive result.



# Vertical and Perinatal Transmission of Hepatitis C<sup>1,7,8</sup>



## Footnotes

- a) Transmission of hepatitis C from HCV RNA positive mother to baby occurs in 3-6%. Most cases occur as a result of perinatal transmission, usually during birth, although in utero transmission has been suggested in up to one-third<sup>9</sup>. The transmission rate is increased 3 to 4 fold in HIV-HCV co-infection and with prolonged rupture of membranes<sup>10</sup>. Transmission via breastfeeding is rare<sup>11,12</sup>. For women with on-going risk factors for HCV who have a negative RNA test, consideration should be given to a further confirmatory NAAT test in the third trimester.
- b) For women who have acquired infection during pregnancy, but have cleared viraemia, the baby should be followed up as described in this algorithm.
- c) For babies born to a woman who has injected drugs, when the mother is unavailable for testing, test the baby for HCV antibody and follow the algorithm if the baby is HCV antibody positive. If the baby is HCV antibody negative then this is highly predictive of absence of infection providing the exposure risk is more than 6 months ago<sup>5</sup>.
- d) Mothers with evidence of hepatitis C antibodies who are stably HCV RNA negative are highly unlikely to transmit HCV to the baby<sup>4-6</sup>. Babies born from HCV RNA PCR negative, anti-HCV antibody positive mothers do not require routine testing, however testing may be considered dependent on local policy<sup>3</sup>.
- e) It should be noted that other guidelines do not always advocate early NAAT testing in children<sup>3</sup>.
- f) HCV RNA assay target sensitivity level of 50 IU/mL or lower<sup>2</sup>.
- g) Sufficient sample should be taken to do both the antibody and NAAT test; this should be included in the local user manual. If there is insufficient sample for both, the antibody test should be done rather than NAAT.
- h) Combined HCV antigen/antibody or HCV antigen only assays can also be used<sup>13,14</sup>. These assays generally have a sensitivity of ~1000-5000 IU/mL and may therefore miss about 3% of viraemia cases<sup>15-19</sup>. Precise analytical sensitivity and clinical sensitivity varies from assay to assay, and should be carefully assessed before the assay is put into service<sup>20-25</sup>. If antigen negative, ensure that NAAT test is performed.
- i) A negative HCV RNA NAAT result may be observed in infected children with fluctuations in viraemia, thus an anti-HCV antibody test should be carried out between 12–18 months<sup>26,27</sup>.
- j) Might reflect resolution of infection (>25% resolve), fluctuating RNA level or a laboratory error.
- k) Request repeat sample. Laboratories may wish to repeat discordant results.

## Notification to PHE<sup>28,29</sup> or Equivalent in the Devolved Administrations<sup>30-33</sup>

---

The Health Protection (Notification) regulations 2010 require diagnostic laboratories to notify Public Health England (PHE) when they identify the causative agents that are listed in Schedule 2 of the Regulations. Notifications must be provided in writing, on paper or electronically, within seven days. Urgent cases should be notified orally and as soon as possible, recommended within 24 hours. These should be followed up by written notification within seven days.

For the purposes of the Notification Regulations, the recipient of laboratory notifications is the local PHE Health Protection Team. If a case has already been notified by a registered medical practitioner, the diagnostic laboratory is still required to notify the case if they identify any evidence of an infection caused by a notifiable causative agent.

Notification under the Health Protection (Notification) Regulations 2010 does not replace voluntary reporting to PHE. The vast majority of NHS laboratories voluntarily report a wide range of laboratory diagnoses of causative agents to PHE and many PHE Health protection Teams have agreements with local laboratories for urgent reporting of some infections. This should continue.

**Note:** The Health Protection Legislation Guidance (2010) includes reporting of Human Immunodeficiency Virus (HIV) & Sexually Transmitted Infections (STIs), Healthcare Associated Infections (HCAs) and Creutzfeldt–Jakob disease (CJD) under ‘Notification Duties of Registered Medical Practitioners’: it is not noted under ‘Notification Duties of Diagnostic Laboratories’.

<https://www.gov.uk/government/organisations/public-health-england/about/our-governance#health-protection-regulations-2010>

Other arrangements exist in [Scotland](#)<sup>30,31</sup>, [Wales](#)<sup>32</sup> and [Northern Ireland](#)<sup>33</sup>.

## References

---

1. Davison SM, Mieli-Vergani G, Sira J, Kelly DA. Perinatal hepatitis C virus infection: diagnosis and management. *Arch Dis Child* 2006;91:781-5.
2. European association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. *J Hepatol* 2011;55:245-64.
3. Scottish Intercollegiate Guidelines Network. SIGN 133: Management of Hepatitis C. 2013.
4. Resti M, Azzari C, Mannelli F, Moriondo M, Novembre E, de MM, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. *BMJ* 1998;317:437-41.
5. Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. *European Paediatric Hepatitis C Virus Infection. J Infect Dis* 2000;181:419-24.
6. Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. *Int J Epidemiol* 1998;27:108-17.
7. Resti M, Bortolotti F, Vajro P, Maggiore G. Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers. *Dig Liver Dis* 2003;35:453-7.
8. Dunn DT, Gibb DM, Healy M, Goodall RL, Butler K, Cafferkey M, et al. Timing and interpretation of tests for diagnosing perinatally acquired hepatitis C virus infection. *Pediatr Infect Dis J* 2001;20:715-6.
9. Mok J, Pembrey L, Tovo PA, Newell ML. When does mother to child transmission of hepatitis C virus occur? *Arch Dis Child Fetal Neonatal Ed* 2005;90:F156-F160.
10. Pembrey L, Newell ML, Tovo PA. The management of HCV infected pregnant women and their children European paediatric HCV network. *J Hepatol* 2005;43:515-25.
11. Indolfi G, Resti M. Perinatal transmission of hepatitis C virus infection. *J Med Virol* 2009;81:836-43.
12. Arshad M, El Kamary SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period--are they opportunities for treatment? *J Viral Hepat* 2011;18:229-36.
13. Ansaldi F, Bruzzone B, Testino G, Bassetti M, Gasparini R, Crovari P, et al. Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection. *J Viral Hepat* 2006;13:5-10.
14. Tillmann HL. Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment. *World J Gastroenterol* 2014;20:6701-6.
15. Gaudy C, Thevenas C, Tichet J, Mariotte N, Goudeau A, Dubois F. Usefulness of the hepatitis C virus core antigen assay for screening of a population undergoing routine medical checkup. *J Clin Microbiol* 2005;43:1722-6.
16. Hayashi K, Hasuike S, Kusumoto K, Ido A, Uto H, Kenji N, et al. Usefulness of a new immuno-radiometric assay to detect hepatitis C core antigen in a community-based population. *J Viral Hepat* 2005;12:106-10.

17. Leary TP, Gutierrez RA, Muerhoff AS, Birkenmeyer LG, Desai SM, Dawson GJ. A chemiluminescent, magnetic particle-based immunoassay for the detection of hepatitis C virus core antigen in human serum or plasma. *J Med Virol* 2006;78:1436-40.
18. Ravera G, Bottaro LC, Franceschini M, Morando A, De PM, Zare M, et al. Reliability and diagnostic use of a test for the search of the hepatitis C virus Ag (AgHCV). *Hepatogastroenterology* 2006;53:753-6.
19. Tobler LH, Stramer SL, Lee SR, Baggett D, Wright D, Hirschhorn D, et al. Performance of ORTHO HCV core antigen and trak-C assays for detection of viraemia in pre-seroconversion plasma and whole blood donors. *Vox Sang* 2005;89:201-7.
20. Chakravarti A, Chauhan MS, Dogra G, Banerjee S. Hepatitis C virus core antigen assay: can we think beyond convention in resource limited settings? *Braz J Infect Dis* 2013;17:369-74.
21. Gu S, Liu J, Zhang H, Gu B, Lai H, Zhou H, et al. Core antigen tests for hepatitis C virus: a meta-analysis. *Mol Biol Rep* 2012;39:8197-208.
22. Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. *Clin Infect Dis* 2012;55 Suppl 1:S43-S48.
23. Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, et al. Is hepatitis C virus core antigen an adequate marker for community screening? *J Clin Microbiol* 2012;50:1989-93.
24. Ottiger C, Gygli N, Huber AR. Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples. *J Clin Virol* 2013;58:535-40.
25. Medici MC, Furlini G, Rodella A, Fuertes A, Monachetti A, Calderaro A, et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. *J Clin Virol* 2011;51:264-9.
26. Polywka S, Pembrey L, Tovo PA, Newell ML. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. *J Med Virol* 2006;78:305-10.
27. England K, Pembrey L, Tovo PA, Newell ML. Excluding hepatitis C virus (HCV) infection by serology in young infants of HCV-infected mothers. *Acta Paediatr* 2005;94:444-50.
28. Public Health England. Laboratory Reporting to Public Health England: A Guide for Diagnostic Laboratories. 2013. p. 1-37.
29. Department of Health. Health Protection Legislation (England) Guidance. 2010. p. 1-112.
30. Scottish Government. Public Health (Scotland) Act. 2008 (as amended).
31. Scottish Government. Public Health etc. (Scotland) Act 2008. Implementation of Part 2: Notifiable Diseases, Organisms and Health Risk States. 2009.
32. The Welsh Assembly Government. Health Protection Legislation (Wales) Guidance. 2010.
33. Home Office. Public Health Act (Northern Ireland) 1967 Chapter 36. 1967 (as amended).